Figure 2.
Survival of 122 patients with AML in CR1, CR2, or with more advanced disease treated with reduced-intensity conditioning using the Seattle regimen. Reprinted with permission from Hegenbart U et al. J Clin Oncol. 2006;24:444–453.12
Survival of 122 patients with AML in CR1, CR2, or with more advanced disease treated with reduced-intensity conditioning using the Seattle regimen. Reprinted with permission from Hegenbart U et al. J Clin Oncol. 2006;24:444–453.12
